Safety and Efficacy of Drug Combinations Against Trichuris Trichiura
Information source: DBL -Institute for Health Research and Development
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Parasitic Diseases
Intervention: albendazole (Drug); mebendazole (Drug); ivermectin (Drug); albendazole + ivermectin (Drug); mebendazole + ivermectin (Drug)
Phase: N/A
Status: Completed
Sponsored by: DBL -Institute for Health Research and Development
Summary
This randomised, controlled, double-blinded clinical study investigates the safety and
efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB
and MBD each in combination with IVM in the treatment of Trichuris trichiura in children
aged 5-14 years.
Clinical Details
Official title: Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Study on Trichuris Trichiura.
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Record adverse reactions
Secondary outcome: Efficacy of treatment
Eligibility
Minimum age: 5 Years.
Maximum age: 15 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Those who are enrolled in class one to six
- Are infected with T. trichiura
- Whose parent consent and who are willing to participate
Exclusion Criteria:
- Those with acute and chronic diseases other than T. trichiura
- Those with a history of any serious adverse drug reactions
Locations and Contacts
Vector Control Division, Kampala, Uganda
Additional Information
Starting date: October 2007
Last updated: January 14, 2010
|
